{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T21:48:45Z","timestamp":1781560125426,"version":"3.54.5"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Equity Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recent updates to the Chinese guidelines for dyslipidemia management have reduced the 10-year risk threshold for starting statins in the primary prevention of atherosclerotic heart disease. This study aims to evaluate the potential negative effects of different statin initiation thresholds on diabetes risk in the Chinese population, while also analyzing their health economic implications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>I We developed a microsimulation model based on event probabilities to assess the cost-effectiveness of statin therapy. The model utilized the China-PAR prediction tool for ASCVD risk and incorporated data from a nationally representative survey and published meta-analyses of middle-aged and elderly Chinese populations. Four strategies were evaluated: a 7.5% 10-year risk threshold, the current guideline strategy, and a 15% threshold. For each strategy, we calculated the incremental cost per quality-adjusted life year (QALY) to gain insights into the economic impact of each approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>The incremental cost per QALY for the 10% 10-year risk threshold strategy, compared to the untreated, was $52,218.75. The incremental cost per QALY for the guideline strategy, compared to the 7.5% 10-year risk threshold strategy, was $464,614.36. These results were robust in most sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Maintaining the recommended thresholds outlined in the current guidelines for the management of dyslipidemia may represent a cost-effective option for China at present. Variations in statin prices and the risk of statin-induced diabetes have significant impacts on the cost-effectiveness outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12939-025-02391-9","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T08:59:45Z","timestamp":1737709185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Health economics assessment of statin therapy initiation thresholds for atherosclerosis prevention in China: a cost-effectiveness analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Tianyu","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xihe","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"issue":"24","key":"2391_CR1","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1001\/jama.2021.22208","volume":"326","author":"L Wang","year":"2021","unstructured":"Wang L, et al. Prevalence and treatment of diabetes in China, 2013\u20132018. JAMA. 2021;326(24):2498\u2013506.","journal-title":"JAMA"},{"issue":"10015","key":"2391_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0140-6736(15)00551-6","volume":"387","author":"M Zhou","year":"2016","unstructured":"Zhou M, et al. Cause-specific mortality for 240 causes in China during 1990\u20132013: a systematic subnational analysis for the global burden of Disease Study 2013. Lancet. 2016;387(10015):251\u201372.","journal-title":"Lancet"},{"issue":"9882","key":"2391_CR3","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1016\/S0140-6736(13)61097-1","volume":"381","author":"G Yang","year":"2013","unstructured":"Yang G, et al. Rapid health transition in China, 1990\u20132010: findings from the global burden of Disease Study 2010. Lancet. 2013;381(9882):1987\u20132015.","journal-title":"Lancet"},{"key":"2391_CR4","unstructured":"Joint committee for guideline, r., 2016 Chinese guidelines for the management of dyslipidemia in adults. J Geriatr Cardiol, 2018;15(1):1\u201329."},{"key":"2391_CR5","doi-asserted-by":"crossref","unstructured":"Grundy SM, NLA\/PCNA Guideline on the Management of Blood Cholesterol. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/. A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019;139(25):e1082-e1143.","DOI":"10.1161\/CIR.0000000000000698"},{"key":"2391_CR6","unstructured":"guideline CG181, N.I.C.E., Cardiovascular disease: risk assessment and reduction, including lipid modification. Methods. 2023, London."},{"key":"2391_CR7","volume-title":"Risk estimation and the prevention of cardiovascular disease","author":"SIG Network","year":"2007","unstructured":"Network SIG. Risk estimation and the prevention of cardiovascular disease. Edinburgh: SIGN; 2007."},{"key":"2391_CR8","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/1471-2458-12-398","volume":"12","author":"LJ Cobiac","year":"2012","unstructured":"Cobiac LJ, et al. Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study. BMC Public Health. 2012;12:398.","journal-title":"BMC Public Health"},{"issue":"2","key":"2391_CR9","first-page":"102","volume":"2","author":"XL Yang","year":"2016","unstructured":"Yang XL, et al. Risk stratification of atherosclerotic cardiovascular disease in Chinese adults. Chronic Dis Transl Med. 2016;2(2):102\u20139.","journal-title":"Chronic Dis Transl Med"},{"key":"2391_CR10","doi-asserted-by":"publisher","first-page":"205031211560551","DOI":"10.1177\/2050312115605518","volume":"3","author":"RD Beckett","year":"2015","unstructured":"Beckett RD, Schepers SM, Gordon SK. Risk of new-onset diabetes associated with statin use[J]. SAGE Open Med. 2015;3:2050312115605518.","journal-title":"SAGE Open Med"},{"issue":"5","key":"2391_CR11","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.numecd.2017.03.001","volume":"27","author":"M Casula","year":"2017","unstructured":"Casula M, et al. Statin use and risk of new-onset diabetes: a meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. 2017;27(5):396\u2013406.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"12","key":"2391_CR12","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1001\/jamainternmed.2021.5714","volume":"181","author":"IA Mansi","year":"2021","unstructured":"Mansi IA, et al. Association of statin therapy initiation with diabetes progression: a retrospective matched-cohort study. JAMA Intern Med. 2021;181(12):1562\u201374.","journal-title":"JAMA Intern Med"},{"key":"2391_CR13","doi-asserted-by":"crossref","unstructured":"Galicia-Garcia U et al. Statin Treatment-Induced Development of type 2 diabetes: from clinical evidence to mechanistic insights. Int J Mol Sci, 2020;21(13).","DOI":"10.3390\/ijms21134725"},{"key":"2391_CR14","doi-asserted-by":"publisher","first-page":"m997","DOI":"10.1136\/bmj.m997","volume":"369","author":"Y Li","year":"2020","unstructured":"Li Y, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 2020;369:m997.","journal-title":"BMJ"},{"issue":"2","key":"2391_CR15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1001\/jama.2015.6822","volume":"314","author":"A Pandya","year":"2015","unstructured":"Pandya A, et al. Cost-effectiveness of 10-Year risk thresholds for initiation of statin therapy for primary Prevention of Cardiovascular Disease. JAMA. 2015;314(2):142\u201350.","journal-title":"JAMA"},{"key":"2391_CR16","unstructured":"MD W. Population pyramids of the World from 1950 to 2100\u2014China 2022. 2022."},{"issue":"2","key":"2391_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehr205","volume":"33","author":"ZJ Yang","year":"2012","unstructured":"Yang ZJ, et al. Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007\u20132008 China National Diabetes and Metabolic disorders Study. Eur Heart J. 2012;33(2):213\u201320.","journal-title":"Eur Heart J"},{"issue":"6","key":"2391_CR18","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/0002-9343(82)90787-2","volume":"73","author":"JR Beck","year":"1982","unstructured":"Beck JR, et al. A convenient approximation of life expectancy (the DEALE). II. Use in medical decision-making. Am J Med. 1982;73(6):889\u201397.","journal-title":"Am J Med"},{"issue":"9716","key":"2391_CR19","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","volume":"375","author":"N Sattar","year":"2010","unstructured":"Sattar N, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735\u201342.","journal-title":"Lancet"},{"issue":"19","key":"2391_CR20","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1161\/CIRCULATIONAHA.116.022367","volume":"134","author":"X Yang","year":"2016","unstructured":"Yang X, et al. Predicting the 10-Year risks of atherosclerotic Cardiovascular Disease in Chinese Population: the China-PAR Project (Prediction for ASCVD Risk in China). Circulation. 2016;134(19):1430\u201340.","journal-title":"Circulation"},{"issue":"21","key":"2391_CR21","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1161\/CIRCULATIONAHA.105.607499","volume":"114","author":"Y Wu","year":"2006","unstructured":"Wu Y, et al. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults. Circulation. 2006;114(21):2217\u201325.","journal-title":"Circulation"},{"issue":"22","key":"2391_CR22","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1161\/CIRCULATIONAHA.107.735340","volume":"117","author":"JP Greving","year":"2008","unstructured":"Greving JP, et al. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation. 2008;117(22):2875\u201383.","journal-title":"Circulation"},{"issue":"10","key":"2391_CR23","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/pds.4020","volume":"25","author":"D Thakker","year":"2016","unstructured":"Thakker D, et al. Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiol Drug Saf. 2016;25(10):1131\u201349.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2391_CR24","doi-asserted-by":"publisher","first-page":"b2376","DOI":"10.1136\/bmj.b2376","volume":"338","author":"JJ Brugts","year":"2009","unstructured":"Brugts JJ, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.","journal-title":"BMJ"},{"issue":"7268","key":"2391_CR25","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1136\/bmj.321.7268.1084","volume":"321","author":"LA Simons","year":"2000","unstructured":"Simons LA, et al. Discontinuation rates for use of statins are high. BMJ. 2000;321(7268):1084.","journal-title":"BMJ"},{"issue":"4","key":"2391_CR26","doi-asserted-by":"publisher","first-page":"224","DOI":"10.5694\/j.1326-5377.2008.tb01589.x","volume":"188","author":"LA Simons","year":"2008","unstructured":"Simons LA, Ortiz M, Calcino G. Persistence with antihypertensive medication: Australia-wide experience, 2004\u20132006. Med J Aust. 2008;188(4):224\u20137.","journal-title":"Med J Aust"},{"key":"2391_CR27","doi-asserted-by":"crossref","unstructured":"Poznyak A et al. The diabetes Mellitus-Atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci, 2020;21(5).","DOI":"10.3390\/ijms21051835"},{"issue":"2","key":"2391_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11892-017-0837-8","volume":"17","author":"M Laakso","year":"2017","unstructured":"Laakso M, Kuusisto J. Diabetes secondary to treatment with statins. Curr Diab Rep. 2017;17(2):10.","journal-title":"Curr Diab Rep"},{"issue":"3","key":"2391_CR29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4103\/0976-500X.136097","volume":"5","author":"U Aiman","year":"2014","unstructured":"Aiman U, Najmi A, Khan RA. Statin induced diabetes and its clinical implications. J Pharmacol Pharmacother. 2014;5(3):181\u20135.","journal-title":"J Pharmacol Pharmacother"},{"key":"2391_CR30","unstructured":"Organization WH. The global burden of disease: 2004 update. World Health Organization; 2008."},{"issue":"7","key":"2391_CR31","doi-asserted-by":"publisher","first-page":"e65958","DOI":"10.1371\/journal.pone.0065958","volume":"8","author":"Z Tan","year":"2013","unstructured":"Tan Z, et al. Health-related quality of life as measured with EQ-5D among populations with and without specific chronic conditions: a population-based survey in Shaanxi Province, China. PLoS ONE. 2013;8(7):e65958.","journal-title":"PLoS ONE"},{"issue":"20","key":"2391_CR32","doi-asserted-by":"publisher","first-page":"e837","DOI":"10.1097\/MD.0000000000000837","volume":"94","author":"S Wang","year":"2015","unstructured":"Wang S, et al. Direct medical costs of hospitalizations for cardiovascular diseases in Shanghai, China: trends and projections. Med (Baltim). 2015;94(20):e837.","journal-title":"Med (Baltim)"},{"issue":"8","key":"2391_CR33","doi-asserted-by":"publisher","first-page":"e1001860","DOI":"10.1371\/journal.pmed.1001860","volume":"12","author":"D Gu","year":"2015","unstructured":"Gu D, et al. The cost-effectiveness of low-cost essential antihypertensive Medicines for Hypertension Control in China: a modelling study. PLoS Med. 2015;12(8):e1001860.","journal-title":"PLoS Med"},{"issue":"Suppl 1","key":"2391_CR34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1467-789X.2007.00440.x","volume":"9","author":"W Zhao","year":"2008","unstructured":"Zhao W, et al. Economic burden of obesity-related chronic diseases in Mainland China. Obes Rev. 2008;9(Suppl 1):62\u20137.","journal-title":"Obes Rev"},{"issue":"3","key":"2391_CR35","first-page":"309","volume":"20","author":"S Sun","year":"2011","unstructured":"Sun S, et al. Population health status in China: EQ-5D results, by age, sex and socio-economic status. Natl Health Serv Surv 2008 Qual Life Res. 2011;20(3):309\u201320.","journal-title":"Natl Health Serv Surv 2008 Qual Life Res"},{"issue":"6","key":"2391_CR36","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s11655-014-1749-y","volume":"21","author":"X Wang","year":"2015","unstructured":"Wang X, et al. Guideline for postmarketing Chinese medicine pharmacoeconomic evaluation. Chin J Integr Med. 2015;21(6):473\u201380.","journal-title":"Chin J Integr Med"},{"issue":"1","key":"2391_CR37","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/heapol\/czw096","volume":"32","author":"LA Robinson","year":"2017","unstructured":"Robinson LA, et al. Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds. Health Policy Plan. 2017;32(1):141\u20135.","journal-title":"Health Policy Plan"},{"key":"2391_CR38","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/1472-6963-14-284","volume":"14","author":"F Bleibler","year":"2014","unstructured":"Bleibler F, et al. Expected lifetime numbers and costs of fractures in postmenopausal women with and without osteoporosis in Germany: a discrete event simulation model. BMC Health Serv Res. 2014;14:284.","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"2391_CR39","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/0272989X12454579","volume":"32","author":"DM Eddy","year":"2012","unstructured":"Eddy DM, et al. Model transparency and validation: a report of the ISPOR-SMDM modeling Good Research practices Task Force-7. Med Decis Mak. 2012;32(5):733\u201343.","journal-title":"Med Decis Mak"},{"issue":"4","key":"2391_CR40","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, et al. AdViSHE: A Validation-Assessment Tool of Health-Economic models for decision makers and model users. PharmacoEconomics. 2016;34(4):349\u201361.","journal-title":"PharmacoEconomics"},{"issue":"8","key":"2391_CR41","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1161\/CIRCULATIONAHA.116.025250","volume":"135","author":"W Wang","year":"2017","unstructured":"Wang W, et al. Prevalence, incidence, and mortality of stroke in China: results from a Nationwide Population-based survey of 480 687 adults. Circulation. 2017;135(8):759\u201371.","journal-title":"Circulation"},{"key":"2391_CR42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jhealeco.2018.05.002","volume":"60","author":"J Boone","year":"2018","unstructured":"Boone J. Basic versus supplementary health insurance: Access to care and the role of cost effectiveness. J Health Econ. 2018;60:53\u201374.","journal-title":"J Health Econ"},{"issue":"10059","key":"2391_CR43","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins R, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532\u201361.","journal-title":"Lancet"},{"issue":"9","key":"2391_CR44","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.2174\/1381612820666141013134447","volume":"21","author":"I Simic","year":"2015","unstructured":"Simic I, Reiner Z. Adverse effects of statins - myths and reality. Curr Pharm Des. 2015;21(9):1220\u20136.","journal-title":"Curr Pharm Des"},{"issue":"2","key":"2391_CR45","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1056\/NEJMms1409015","volume":"372","author":"L Rosenbaum","year":"2015","unstructured":"Rosenbaum L. Beyond belief\u2013how people feel about taking medications for heart disease. N Engl J Med. 2015;372(2):183\u20137.","journal-title":"N Engl J Med"},{"issue":"3","key":"2391_CR46","doi-asserted-by":"publisher","first-page":"e0193273","DOI":"10.1371\/journal.pone.0193273","volume":"13","author":"X Xiong","year":"2018","unstructured":"Xiong X, et al. Impact of universal medical insurance system on the accessibility of medical service supply and affordability of patients in China. PLoS ONE. 2018;13(3):e0193273.","journal-title":"PLoS ONE"},{"issue":"7","key":"2391_CR47","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40273-019-00791-8","volume":"37","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Ni W. Economic evaluation of the 2016 Chinese Guideline and Alternative Risk thresholds of initiating statin therapy for the management of atherosclerotic Cardiovascular Disease. PharmacoEconomics. 2019;37(7):943\u201352.","journal-title":"PharmacoEconomics"},{"issue":"8","key":"2391_CR48","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/j.1524-4733.2010.00775.x","volume":"13","author":"JJ Caro","year":"2010","unstructured":"Caro JJ, Moller J, Getsios D. Discrete event simulation: the preferred technique for health economic evaluations? Value Health. 2010;13(8):1056\u201360.","journal-title":"Value Health"},{"issue":"5","key":"2391_CR49","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/j.1524-4733.2008.00497.x","volume":"12","author":"M Hiligsmann","year":"2009","unstructured":"Hiligsmann M, et al. Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health. 2009;12(5):687\u201396.","journal-title":"Value Health"},{"key":"2391_CR50","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijcard.2018.06.091","volume":"270","author":"Z Ademi","year":"2018","unstructured":"Ademi Z, Zomer E, Tonkin A, et al. Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: an Australian perspective[J]. Int J Cardiol. 2018;270:54\u20139.","journal-title":"Int J Cardiol"},{"issue":"4","key":"2391_CR51","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1517\/14740331003662620","volume":"9","author":"DM Boudreau","year":"2010","unstructured":"Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf. 2010;9(4):603\u201321.","journal-title":"Expert Opin Drug Saf"},{"key":"2391_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13613-015-0049-9","volume":"5","author":"DR Ouellette","year":"2015","unstructured":"Ouellette DR, et al. Sepsis outcomes in patients receiving statins prior to hospitalization for sepsis: comparison of in-hospital mortality rates between patients who received atorvastatin and those who received simvastatin. Ann Intensive Care. 2015;5:9.","journal-title":"Ann Intensive Care"},{"issue":"2","key":"2391_CR53","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3138\/ptc.2012-65","volume":"66","author":"P Mendes","year":"2014","unstructured":"Mendes P, Robles PG, Mathur S. Statin-induced rhabdomyolysis: a comprehensive review of case reports. Physiother Can. 2014;66(2):124\u201332.","journal-title":"Physiother Can"},{"key":"2391_CR54","doi-asserted-by":"crossref","unstructured":"Ganda OP. Statin-induced diabetes: incidence, mechanisms, and implications. F1000Res, 2016;5.","DOI":"10.12688\/f1000research.8629.1"}],"container-title":["International Journal for Equity in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12939-025-02391-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12939-025-02391-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12939-025-02391-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T09:01:54Z","timestamp":1737709314000},"score":1,"resource":{"primary":{"URL":"https:\/\/equityhealthj.biomedcentral.com\/articles\/10.1186\/s12939-025-02391-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2391"],"URL":"https:\/\/doi.org\/10.1186\/s12939-025-02391-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.08.03.23293584","asserted-by":"object"}]},"ISSN":["1475-9276"],"issn-type":[{"value":"1475-9276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"21 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}